Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32997907

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2020 Oct 1
First author
Herbst RS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2021 Feb 11;384(6):583-584. doi: 10.1056/NEJMc2032432.
    note
    Source null
    related pmid
    33567200
    relationship
    Comment in
  2. citation
    N Engl J Med. 2021 Feb 11;384(6):584. doi: 10.1056/NEJMc2032432.
    note
    Source null
    related pmid
    33567201
    relationship
    Comment in

Authors and identifiers

  1. name
    Herbst RS
    type
    Author
  2. name
    Giaccone G
    type
    Author
  3. name
    de Marinis F
    type
    Author
  4. name
    Reinmuth N
    type
    Author
  5. name
    Vergnenegre A
    type
    Author
  6. name
    Barrios CH
    type
    Author
  7. name
    Morise M
    type
    Author
  8. name
    Felip E
    type
    Author
  9. name
    Andric Z
    type
    Author
  10. name
    Geater S
    type
    Author
  11. name
    Özgüroğlu M
    type
    Author
  12. name
    Zou W
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Herbst RS
    type
    Author
  2. name
    Giaccone G
    type
    Author
  3. name
    de Marinis F
    type
    Author
  4. name
    Reinmuth N
    type
    Author
  5. name
    Vergnenegre A
    type
    Author
  6. name
    Barrios CH
    type
    Author
  7. name
    Morise M
    type
    Author
  8. name
    Felip E
    type
    Author
  9. name
    Andric Z
    type
    Author
  10. name
    Geater S
    type
    Author
  11. name
    Özgüroğlu M
    type
    Author
  12. name
    Zou W
    type
    Author
bibliography ids
  1. nci-bib-7c8f51090442a1e54fab682f
book metadata
content sha256
43df546c80774b32d1e0820de56c79f981e0ac9e89d1822c98a646ac280cee9b
document type
citation
dois
  1. 10.1056/NEJMoa1917346
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:32997907
immutable id
pubmed:32997907@43df546c80774b32d1e0820de56c79f981e0ac9e89d1822c98a646ac280cee9b
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
14
name
The New England journal of medicine
nlm unique id
0255562
pages
1328-1339
volume
383
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2021 Feb 11;384(6):583-584. doi: 10.1056/NEJMc2032432.
    note
    Source null
    related pmid
    33567200
    relationship
    Comment in
  2. citation
    N Engl J Med. 2021 Feb 11;384(6):584. doi: 10.1056/NEJMc2032432.
    note
    Source null
    related pmid
    33567201
    relationship
    Comment in
outcomes validated
false
pmid
32997907
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
66f06921b5c440a2ea5cf2bbd331fa49b5552f30dce30656547c05a4d98af83f
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Oct 1
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32997907/
title
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Preserved source evidence · Not medical advice